Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally admin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Rosenke, Kyle, Hansen, Frederick, Schwarz, Benjamin, Feldmann, Friederike, Haddock, Elaine, Rosenke, Rebecca, Barbian, Kent, Meade-White, Kimberly, Okumura, Atsushi, Leventhal, Shanna, Hawman, David W., Ricotta, Emily, Bosio, Catharine M., Martens, Craig, Saturday, Greg, Feldmann, Heinz, Jarvis, Michael A.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052374/
https://ncbi.nlm.nih.gov/pubmed/33863887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-22580-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados